Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO.

Nag SS, Daniel GW, Bullano MF, Kamal-Bahl S, Sajjan SG, Hu H, Alexander C.

J Manag Care Pharm. 2007 Oct;13(8):652-63.

2.

Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.

Cziraky MJ, Watson KE, Talbert RL.

J Manag Care Pharm. 2008 Oct;14(8 Suppl):S3-28; quiz S30-1. Review.

PMID:
19891279
3.

Cholesterol and atherosclerosis: a contemporary perspective.

Kashyap ML.

Ann Acad Med Singapore. 1997 Jul;26(4):517-23. Review.

PMID:
9395824
4.

Method of LDL cholesterol measurement influences classification of LDL cholesterol treatment goals: clinical research study.

Agrawal M, Spencer HJ, Faas FH.

J Investig Med. 2010 Dec;58(8):945-9. doi: 10.231/JIM.0b013e3181fb7ca7. Review.

5.

[Modification of coronary heart disease by drug treatment of lipid metabolism disorders].

Richter WO, Schwandt P.

Versicherungsmedizin. 1995 Apr 1;47(2):63-5. Review. German.

PMID:
7762119
6.

Drug treatment of hyperlipidemia in women.

Walsh JM, Pignone M.

JAMA. 2004 May 12;291(18):2243-52. Review.

PMID:
15138247
7.

Oxidized LDL and coronary heart disease.

Holvoet P.

Acta Cardiol. 2004 Oct;59(5):479-84. Review.

PMID:
15529550
8.

Impact of Pharmacy-led Dyslipidemia Interventions on Medication Safety and Therapeutic Failure in Patients.

Weaver JG, McManus JE, Leung T, Mangione RB, Snow HR, Hackworth SK.

In: Henriksen K, Battles JB, Marks ES, Lewin DI, editors. Advances in Patient Safety: From Research to Implementation (Volume 1: Research Findings). Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Feb.

9.

Addressing cardiovascular disease in women: focus on dyslipidemia.

Meagher EA.

J Am Board Fam Pract. 2004 Nov-Dec;17(6):424-37. Review.

10.

Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies.

Mitchell S, Roso S, Samuel M, Pladevall-Vila M.

BMC Cardiovasc Disord. 2016 Apr 26;16:74. doi: 10.1186/s12872-016-0241-3. Review.

11.
12.

Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review.

Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, Wensley F, Higgins JP, Lennon L, Eiriksdottir G, Rumley A, Whincup PH, Lowe GD, Gudnason V.

PLoS Med. 2008 Apr 8;5(4):e78. doi: 10.1371/journal.pmed.0050078. Review.

13.

Is diabetes a coronary risk equivalent? Systematic review and meta-analysis.

Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I.

Diabet Med. 2009 Feb;26(2):142-8. doi: 10.1111/j.1464-5491.2008.02640.x. Review.

PMID:
19236616
14.

The UKPDS: implications for the dyslipidaemic patient.

Holman R.

Acta Diabetol. 2001;38 Suppl 1:S9-14. Review.

PMID:
11829452
15.

[Diabetes mellitus and coronary artery disease. Update on diagnosis and drug therapy].

Marx N, Blessing E.

Dtsch Med Wochenschr. 2007 May 11;132(19):1034-8. Review. German. No abstract available.

PMID:
17476633
16.

Lipid levels and renal function decline in pre-dialysis patients.

de Goeij MC, Rotmans JI, Matthijssen X, de Jager DJ, Dekker FW, Halbesma N; PREPARE-2 Study Group.

Nephron Extra. 2015 Feb 4;5(1):19-29. doi: 10.1159/000371410. eCollection 2015 Jan-Apr. Review.

17.

The impact of premorbid and postmorbid depression onset on mortality and cardiac morbidity among patients with coronary heart disease: meta-analysis.

Leung YW, Flora DB, Gravely S, Irvine J, Carney RM, Grace SL.

Psychosom Med. 2012 Oct;74(8):786-801. doi: 10.1097/PSY.0b013e31826ddbed. Epub 2012 Sep 21. Review.

18.

Mendelian randomization studies: using naturally randomized genetic data to fill evidence gaps.

Ference BA.

Curr Opin Lipidol. 2015 Dec;26(6):566-71. doi: 10.1097/MOL.0000000000000247. Review.

PMID:
26780009
19.

Lipid management in patients with type 2 diabetes.

Daniel MJ.

Am Health Drug Benefits. 2011 Sep;4(5):312-22. Review.

20.

Indications for lipid-lowering drugs.

Davignon J.

Eur J Clin Pharmacol. 1991;40 Suppl 1:S3-10. Review.

PMID:
2044639

Supplemental Content

Support Center